SynthesisOncogene2025
Of travelling homeoproteins and medulloblastomas.
Synthesis in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Medulloblastomas are the most common solid paediatric cancers. Their prognosis largely depends on tumour subtype and expression level of transcription factor such as Orthodenticle homeobox 2 (OTX2). OTX2 is an homeoprotein that maintains stemness and initiates oncogenic pathways. Additionally, as many other homeoproteins, OTX2 is able to travel between cells and to modify the transcriptional activity of recipient ones. After identifying travelling proteins in in vivo models, a systematic review of the literature highlighted that at least eleven travelling homeoproteins are associated with medulloblastoma: Cut like homeobox 1 (CUX1), Engrailed homeobox 1 and 2 (EN1 and EN2), Insulin gene enhancer protein ISL-1 (ISL1), LIM homeobox 1 (LHX1), Homeobox protein Nkx-2.2 (NKX2.2), OTX2, Paired box protein Pax-5,6 and 8 (PAX5, PAX6 and PAX8), as well as POU domain, class 5, transcription factor 1 (POU5F1). Overexpression of some of these homeoprotein-coding gene including OTX2 and POU5F1 was found to be associated with poor prognosis, while overexpression of PAX8 seems to have a protective effect, with a significantly better overall and progression-free survival. Research efforts to better understand the transfer mechanisms and intracellular targets of these transcription factors may offer a new range of therapeutics tools, by interfering with these roaming oncoproteins to circumscribe their associated chain reaction of genetic deregulation, or by providing protective homeoprotein supplementation with the aim of stemming tumour development by direct cancer cell penetration and reprograming.
Indexed as
Identifiers
40760093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.